1 / 29

PRECLINICAL PHARMACOLOGY TOXICOLOGY OF ANTI-NEOPLASTIC AGENTS

OBJECTIVES OF PRECLINICAL PHARMACOLOGY STUDIES FOR ANTI-NEOPLASTIC DRUGS. Development of Sensitive Analytical Methods for Drugs in Biological Fluids & Tissues ...

libitha
Télécharger la présentation

PRECLINICAL PHARMACOLOGY TOXICOLOGY OF ANTI-NEOPLASTIC AGENTS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. PRECLINICAL PHARMACOLOGY & TOXICOLOGY OF ANTI-NEOPLASTIC AGENTS????THE NCI PERSPECTIVE Joseph E. Tomaszewski, Ph.D. Toxicology & Pharmacology Branch DTP, DCTD, NCI

    2. PRECLINICAL PHARMACOLOGY & TOXICOLOGY: WHY? Balance of: Regulatory Issues Need for information Science Practical Considerations Preclinical Costs versus Patient Cost

    3. REASONS FOR TERMINATION OF DEVELOPMENT OF NCEs

    4. REGULATORY CONSIDERATIONS FOR PRE-CLINICAL DEVELOPMENT OF ANTICANCER DRUGS [DeGeorge, et al, CCP (1998) 41: 173-185]

    5. FDA PRECLINICAL PHARMACOLOGY & TOXICOLOGY REQUIREMENTS DRUGS Two Species - Rodent & Non-rodent Clinical Route & Schedule Follow NCI Guidelines Pharmacokinetics - Optional

    6. REPRESENTATIVE SURFACE AREA TO WEIGHT RATIOS (km) FOR VARIOUS SPECIES 1 ((Freireich, et al, Cancer Chemother Repts, 1966, 50, 219-244))

    7. NCI STANDARDIZED PRECLINICAL TOXICOLOGY PROTOCOLS FOR ANTI-NEOPLASTIC AGENTS (1980 - 1988) Mouse Lethality Studies Dog Toxicity Studies Rodent (Rat) Toxicity Studies Determine LD10 on Dx1 & Dx5 Schedules Assess safety of 1/10 LD10 Determine DLTs on Dx1 & Dx5 Schedules. Assess safety of 1/10 LD10 Determine DLTs on Dx1 & Dx5 Schedules.

    8. T&PB DRUG EVALUATION PHILOSOPHY Agent-Directed Studies Pharmacologically (PK/PD) - Guided Integrate With Preclinical Efficacy Data & the Proposed Clinical Protocol Rational Evaluation of Role of Schedule Dependence, Pharmacodynamics, Pharmacokinetics & Metabolism in the Development of Toxicity Relate Drug Levels and/or AUC (Plasma &/or Tissue), Biomarkers to Safety and to Occurrence & Severity of Toxicity Extrapolate Toxic Effects Across Species

    9. AGENT-DIRECTED versus STANDARD PROTOCOL DRUG DEVELOPMENT Greater Scientific Basis for Development Permits Greater Flexibility Data Rich IND Submission to Support Phase I Preclinical Potential ….. Less Expensive Permits PK/PD-Guided Dose Escalation in Phase I Optimal Schedule ….. Greater Chance of Success? Patients ….. Greater Chance of Effective Therapy?

    10. OBJECTIVES OF PRECLINICAL PHARMACOLOGY STUDIES FOR ANTI-NEOPLASTIC DRUGS Development of Sensitive Analytical Methods for Drugs in Biological Fluids & Tissues Determine In Vitro Stability and Protein Binding Determine Pharmacokinetics in Various Species Identification and Analysis of Metabolites Define Optimal Dose Schedule and Blood Sampling Times Define CP and/or AUC with Efficacy, Safety & Toxicity Analog Evaluation - Determine Optimal Development Candidate

    11. KEY PHARMACOLOGY CONTRIBUTIONS TO DRUG DEVELOPMENT

    12. OBJECTIVES OF PRECLINICAL TOXICOLOGY STUDIES FOR ANTI-NEOPLASTIC DRUGS DETERMINE IN APPROPRIATE ANIMAL MODELS: The Maximum Tolerated Dose ( MTD ) Dose Limiting Toxicities ( DLT ) Schedule-Dependent Toxicity Reversibility of Adverse Effects A Safe Clinical Starting Dose

    13. ADDITIONAL AGENT-DIRECTED TOXICOLOGY STUDY REQUIREMENTS Attain Efficacious Drug Levels in Plasma In Vivo Correlate Drug Plasma Levels and/or AUC with Toxicity and Safety Across Species Ameliorate Toxicity by Change in Route/Schedule Compare Toxicity with Accepted Clinical Agents as Necessary

    14. SCHEDULE and ROUTE versus TOXICITY Pyrazoloacridine: Bolus iv Neurotoxicity 1 Hr civ Bone Marrow Penclomedine: Bolus iv Neurotoxicity 1 Hr Dx5 BM (& Neuro) 5 Hr civ Neuro & Death Oral BM O6 –Benzylguanine: Bolus CNS, HR ? Infusion Neutrophilia

    15. DEVELOPMENT EXAMPLE:9-AMINO-20[S]CAMPTOTHECIN (NSC-603071)

    16. 9-AMINO-20[S]CAMPTOTHECIN (NSC-603071): PRECLINICAL EFFICACY & PK RESULTS EFFICACY Best: Rx sc, suspension, q4Dx8 Good: Rx sc, solution, Dx32 None: Rx sc, solution, q4Dx8

    17. 9-AMINO-20[S]CAMPTOTHECIN (NSC-603071): PRECLINICAL PK & TOXICOLOGY STUDIES Mice: Pharmacokinetics - iv and sc Repeated (q4Dx3) sc Dose Toxicity Study Rats: Pharmacokinetics - Bolus iv 72 Hr civ IND-Directed Toxicity Study Dogs: PK/Dose RF Study - Bolus iv 48 Hr civ Dose RF Toxicity Study 72 Hr civ Dose RF Toxicity Study 72 Hr civ IND-Directed Toxicity Study In Vitro: Murine, Canine, Human CFUGM

    18. 9-AMINO-20[S]CAMPTOTHECIN (NSC-603071): IN VITRO BONE MARROW DATA

    19. 9-AMINO[20S]CAMPTOTHECIN (NSC 603071): IN VITRO & IN VIVO TOXICITY DATA

    20. 9-AMINO[20S]CAMPTOTHECIN (NSC 603071): DEVELOPMENT CONCLUSIONS Bone Marrow and GI Toxicity are Dose Limiting in Mice, Rats and Dogs; and Should be in Man. Dogs are the Most Sensitive Species. In Vitro Bone Marrow Data Predicts that Man will be as Sensitive as the Dog. The MTD in Man & Dog Should be Comparable. 9-AC Lactone Plasma Levels and AUC Required for Efficacy in the Mouse are Not Achievable in the Dog.

    21. 9-AMINO-20[S]CAMPTOTHECIN (NSC-603071):CORRELATION OF EFFICACY WITH TOXICITY & PHARMACOKINETICS

    22. ACKNOWLEDGEMENTS T&PB Contractors Pharmacology Mayo Foundation Ohio State University Southern Research Univ Alabama Univ Pittsburgh Univ Texas - MDA

    23. ACKNOWLEDGEMENTS T&PB Staff PK: Joseph M. Covey, Ph.D. PK: Julie K Rhie, R.Ph., Ph.D. Tox: Susan J. Donohue, Ph.D. Tox: Elizabeth R. Glaze, Ph.D. Tox: Karen M. Schweikart, Ph.D. Tox: Adaline C. Smith, Ph.D., DABT Sec: Victoria Cordelli

    24. T&P CONTACT INFORMATION Phone No: 301-496-8777 Fax No: 301-480-4836 E-mail: ncidtptpbinfo@mail.nih.gov Web Address: http://dtp.nci.nih.gov/branches/tpb/index.html

    25. Thank you, Are there any Questions?

    29. EORTC MINIMUM REQUIREMENTS FOR THE TOXICOLOGY OF A NEW CYTOSTATIC AGENT FOR PHASE I TRIALS 1987 1995 Dx1 ip Mouse Lethality Study x NA Dx1 iv Mouse Lethality Study x x Dx1 Toxicity Study in Mice x NA Detailed Toxicity in Mice (Clin Prot) NA x Multiple Dose ip Toxicity Study in Mice x NA Toxicity Check in Rats at Clinical Dose x NA Toxicity Study in Rats (Clin Prot) NA x Limited PK Study in Mice (AUC at MTD) NA x

More Related